Reports Q3 revenue $236,000 vs $14.949M last year. Dr. Garry Neil, Chief Executive Officer and Chairman of the Board remarked, “We made significant progress in the third quarter, highlighted by the full debt payoff and divestiture of the 800 series. Our strengthened balance sheet and focused pipeline underscores our unwavering commitment to execute our strategy to progress our promising immunology drug candidates and positions us to consider collaborations, pursue funding for research and development, and bring innovative treatments to market.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AVTX:
- Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates
- Avalo Therapeutics completes divestiture of AVTX-800 series
- Avalo Completes Divestiture of AVTX-800 Series
- Avalo Therapeutics eliminates $35M debt
- Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation
